Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
Saved in:
| Title: | Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. |
|---|---|
| Authors: | D'Alise AM; Nouscom SRL, Rome, Italy., Willis J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duzagac F; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hall MJ; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA., Cruz-Correa M; University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA., Idos GE; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Thirumurthi S; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ballester V; University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA., Leoni G; Nouscom SRL, Rome, Italy., Garzia I; Nouscom SRL, Rome, Italy., Antonucci L; Nouscom SRL, Rome, Italy., De Marco L; Nouscom SRL, Rome, Italy., Micarelli E; Nouscom SRL, Rome, Italy., Deng N; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Seclì L; Nouscom SRL, Rome, Italy., Gogov S; Nouscom AG, Basel, Switzerland., Dong W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jack Lee J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bowen CM; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vornik LA; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Gonzalez A; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Reyes-Uribe L; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Richmond E; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA., Umar A; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA., Brown PH; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sinha KM; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez LM; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.; Department of Surgery, Walter Reed National Military Medical Center, Bethesda, MD, USA., Scarselli E; Nouscom SRL, Rome, Italy. e.scarselli@nouscom.com., Vilar E; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. EVilar@mdanderson.org. |
| Source: | Nature medicine [Nat Med] 2026 Mar; Vol. 32 (3), pp. 1002-1011. Date of Electronic Publication: 2026 Jan 16. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
